Sign Up Today and Learn More About ViaCyte Stock
Invest in or calculate the value of your shares in ViaCyte or other pre-IPO companies through EquityZen's platform.
About ViaCyte Stock
Founded
1999
Headquarters
San Diego, CA, US
Total Funding
202M
Industries
Software, Artificial Intelligence, Data and Analytics
ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
ViaCyte Management
Leadership team at ViaCyte
Senior Vice President, Science & Technology
Allan Robins
Vice President, Business Development and Strategy
Mark Zimmerman
Join now and verify your accreditation status to gain access to:
- ViaCyte Current Valuation
- ViaCyte Stock Price
- ViaCyte Management
- Available deals in ViaCyte and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- ViaCyte Cap Table and Funding History by Share Class and Liquidity Preferences
- ViaCyte Revenue and Financials
- ViaCyte Highlights
- ViaCyte Business Model
- ViaCyte Risk Factors
- ViaCyte Research Report from SACRA Research
Trading ViaCyte Stock
How to invest in ViaCyte stock?
Accredited investors can buy pre-IPO stock in companies like ViaCyte through EquityZen funds. These investments are made available by existing ViaCyte shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell ViaCyte stock?
Shareholders can sell their ViaCyte stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 45K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."